This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

Phase 3

Completed

Conditions: Urinary Bladder Overactive
Urinary Bladder Diseases\Urologic Diseases
Overactive Bladder
Urgency Incontinence

Interventions: Drug: Placebo to match solifenacin succinate
Drug: Mirabegron
Drug: Solifenacin succinate
Drug: Placebo to match mirabegron

Registration Number: NCT01972841

Lead Sponsor: Astellas Pharma Europe B.V.

Brief Summary: The purpose of this study was to examine how well two medicines (solifenacin succinate and mirabegron) combined work compared to each medicine alone in the treatment of bladder problems.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 3527

Inclusion Criteria

Subject was willing and able to complete the micturition diary and questionnaires correctly and able to measure his/her vital signs at home at stipulated time points, using the device provided by the study personnel, and to adequately record the readings;
Subject had symptoms of "wet" OAB (urinary frequency and urgency with incontinence) for at least 3 months;

Exclusion Criteria

Subject had significant PVR volume (> 150 mL);
Subject had a neurological cause for detrusor overactivity (e.g. neurogenic bladder, diabetic neuropathy with autonomic component or bladder involvement, or systemic or central neurological disease such as multiple sclerosis and Parkinson's disease with autonomic component or bladder involvement). An autonomic component could be inferred when autonomic functions were affected, including heart rate, blood pressure, perspiration and digestion.
Subject had an indwelling catheter or practices intermittent self catheterization.
Subject had chronic inflammation such as bladder pain syndrome /interstitial cystitis, symptomatic bladder stones or any previous or current radiation cystitis.
Subject had received intravesical treatment in the past 12 months with e.g., botulinum toxin, resiniferatoxin, capsaicin.
Subject had moderate to severe hepatic impairment
Subject had severe renal impairment
Subject had a clinically significant abnormal ECG
Subject had a concurrent malignancy or history of cancer (except noninvasive skin cancer) within the last 5 years prior to screening.
Subject had an average QTcF interval > 450 ms for males or > 470 ms for females based on the triplicate ECGs completed at Screening or is at risk of QT prolongation (e.g., family history of long QT syndrome, hypokalaemia).
Subject had severe hypertension, which is defined as a sitting average systolic blood pressure ≥ 180 mmHg and/or average diastolic blood pressure ≥ 110 mmHg.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2: Solifenacin 5 mg + Mirabegron 50 mg	Placebo to match mirabegron	Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.
3: Placebo	Placebo to match solifenacin succinate	Participants who received matching placebo once a day for 12 weeks.
5:Mirabegron 25 mg	Mirabegron	Participants who received mirabegron 25 mg once a day for 12 weeks.
5:Mirabegron 25 mg	Placebo to match solifenacin succinate	Participants who received mirabegron 25 mg once a day for 12 weeks.
5:Mirabegron 25 mg	Placebo to match mirabegron	Participants who received mirabegron 25 mg once a day for 12 weeks.
6: Mirabegron 50 mg	Mirabegron	Participants who received mirabegron 50 mg once a day for 12 weeks.
6: Mirabegron 50 mg	Placebo to match solifenacin succinate	Participants who received mirabegron 50 mg once a day for 12 weeks.
1: Solifenacin 5 mg + Mirabegron 25 mg	Placebo to match mirabegron	Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.
6: Mirabegron 50 mg	Placebo to match mirabegron	Participants who received mirabegron 50 mg once a day for 12 weeks.
3: Placebo	Placebo to match mirabegron	Participants who received matching placebo once a day for 12 weeks.
4: Solifenacin 5 mg	Placebo to match mirabegron	Participants who received solifenacin 5 mg once a day for 12 weeks.
1: Solifenacin 5 mg + Mirabegron 25 mg	Mirabegron	Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.
1: Solifenacin 5 mg + Mirabegron 25 mg	Solifenacin succinate	Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.
2: Solifenacin 5 mg + Mirabegron 50 mg	Solifenacin succinate	Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.
2: Solifenacin 5 mg + Mirabegron 50 mg	Mirabegron	Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.
4: Solifenacin 5 mg	Solifenacin succinate	Participants who received solifenacin 5 mg once a day for 12 weeks.

Primary Outcome Measures

Name	Time	Method
Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours	Baseline and EoT (up to 12 weeks)	An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period.
Change From Baseline to EoT in Mean Number of Micturitions Per 24 Hours	Baseline and EoT (up to 12 weeks)	A micturition was defined as any voluntary micturition (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Urgency Incontinence Episodes	Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)
Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Incontinence Episodes Per 24 Hours	Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)	The mean number of urgency incontinence episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.
Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours	Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)	An urgency episode was a complaint of a sudden, compelling desire to pass urine, which was difficult to defer; it was recorded when a micturition or incontinence episode was recorded and the severity of urinary urgency recorded was 3 (severe urgency) or 4 (urgency incontinence) according to the Patient Perception of Intensity of Urgency Scale (PPIUS). The mean number of urgency episodes per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.
Number of Nocturia Episodes at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	A nocturia episode was defined as waking at night 1 or more times to void (i.e., any voiding associated with sleep disturbance between the time the participant went to bed with the intention to sleep until the time the patients got up in the morning with the intention to stay awake). The number of nocturia episodes was the number of times a participant recorded a nocturia episode on valid diary days during the 7-day micturition diary period prior to each visit.
Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Nocturia Episodes	Baseline and weeks 4, 8, 12, and EoT (up to 12 weeks)
Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Nocturia Episodes Per 24 Hours	Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)	The mean number of nocturia episodes per 24hr was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.
Number of Pads Used at Weeks 4, 8, 12 and EoT	Weeks 4, 8 and 12 (up to 12 weeks)	The number of pads used was the number of times a participant recorded a new pad used on valid diary days during the 7-day micturition diary period prior to each visit.
Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Pads Used	Baseline and weeks 4, 8, 12 and EOT (up to 12 weeks)
Change From Baseline to Weeks 4, 8, 12 and EoT in Mean Number of Pads Used Per 24 Hours	Baseline and weeks 4, 8 and 12 (up to 12 weeks)	The mean number of pads used per 24 hours was calculated from data recorded by the participant per day on valid diary days during the 7-day micturition diary period prior to each visit.
Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Sleep	Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)	The Sleep score was calculated by adding 5 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.
Patient's Global Impression of Change (PGIC) Scale: Impression in Bladder Symptoms at Week 12 and EoT	Week 12 and EoT (up to 12 weeks)	The PGIC was a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved).
PGIC Scale: Impression in General Health at Week 12 and EoT	Week 12 and EoT (up to 12 weeks)	The PGIC was a 2-part questionnaire, assessing both the change in the patient's overall condition and change in bladder condition since the start of the study (from very much worse to very much improved).
Number of Incontinence-Free Days at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The number of incontinence-free days was the number of valid diary days during the 7-day micturition diary period with no incontinence episodes recorded.
Number of Days With < 8 Micturitions at Weeks 4, 8, 12 and EoT	Weeks 4, 8,12 and EoT (up to 12 weeks)	The number of days with \< 8 micturitions was the number of valid diary days during the 7-day micturition diary period with less than 8 micturitions per day.
Number of Incontinence-Free Days With < 8 Micturitions at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The number of incontinence-free days with \< 8 micturitions per day was the number of valid diary days during the 7-day micturition diary period with no incontinence episodes recorded and with \< 8 micturitions per day.
Change From Baseline to Weeks 4, 8, 12 and EoT in Patient Perception of Bladder Condition Questionnaire (PPBC)	Baseline and weeks 4, 8, 12, EoT (up to 12 weeks)	The PPBC was a validated, global assessment tool using a 6-point Likert scale on which participants rated their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.
Change From Baseline to Weeks 4, 8 and 12 in the OAB-q Symptom Bother Score	Baseline and weeks 4, 8 and 12	The OAB-q was a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion in the OAB-q (seen in this outcome measure) consisted of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicated an improvement.
Change From Baseline to EoT in European Quality of Life in 5 Dimensions (EQ-5D) Questionnaire Subscale Score: Mobility	Baseline and EoT (up to 12 weeks)	The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).
Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q Health-Related Quality of Life Questionnaire (HRQL) Total Score	Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)	The OAB-q was a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion in the OAB-q (seen in this outcome measure) consisted of 25 HRQL items comprising 4 HRQL subscales (Coping, Concern, Sleep, and Social Interaction), scored 1-6. The total HRQoL score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.
Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Coping	Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)	The Coping score was calculated by adding 8 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.
Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Social	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The Social score was calculated by adding 5 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.
Change From Baseline to Weeks 4, 8, 12 and EoT in OAB-q HRQL Subscale Score: Concern	Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)	The Concern score was calculated by adding 7 response scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.
Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Self-Care	Baseline and EoT (up to 12 weeks)	The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).
Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Usual Activities	Baseline and EoT (up to 12 weeks)	The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).
Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Activity Impairment	Baseline and week 12 and EoT (up to 12 weeks)
Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Pain/Discomfort	Baseline and EoT (up to 12 weeks)	The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).
Change From Baseline to EoT in EQ-5D Questionnaire Subscale Score: Anxiety/Depression	Baseline and EoT (up to 12 weeks)	The EQ-5D questionnaire was an international, standardized, nondisease specific instrument for describing and valuing health status, and has 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension had 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity).
Change From Baseline to Week 12 and EoT in Work Productivity and Activity Impairment: Specific Health Problem Questionnaire (WPAI:SHP) Score: Percent Work Time Missed	Baseline and week 12 and EoT (up to 12 weeks)	The WPAI:SHP was a self-administered questionnaire with 6 questions (Q1=Employment status; Q2=Hours absent from work due to the bladder condition; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the bladder condition on productivity while working; Q6=Impact of the bladder condition on productivity while doing regular daily activities other than work) and a 1-week recall period. WPAI outcomes were expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes. A negative change from baseline indicated improvement.
Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Impairment While Working	Baseline and week 12 and EoT (up to 12 weeks)
Change From Baseline to Week 12 and EoT in WPAI:SHP Score: Percent Overall Work Impairment	Baseline and week 12 and EoT (up to 12 weeks)
Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, at Least 10 Points Improvement on OAB-q HRQL Total Score and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The percentage of participants considered as triple responders, defined as participants with 50% reduction in mean number of incontinence episodes per24 hours compared to baseline, minimal important difference reached (improvement by ≥ 10 points) on the HRQL total score, and ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.
Change From Baseline to Weeks 4, 8 and 12 in TS-VAS	Baseline and week 4, 8 and 12	The TS-VAS was a visual analogue scale which asked participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) on the left to 10 (Yes, completely) on the right. A positive change from baseline indicated improvement.
Percentage of Participants With ≥ 10 Points Improvement From Baseline in the OAB-q Symptom Bother Score at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The percentage of participants with ≥ 10 points improvement from baseline to each visit (weeks 4, 8, 12 and EoT).
Percentage of Participants With 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The percentage of participants with ≥ 50% decrease from baseline in mean number of incontinence episodes per 24 hours at each time point (weeks 4, 8, 12 and EoT).
Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 3 Diary Days at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The percentage of participants with zero incontinence episodes per 24 hours postbaseline in the last 3 days prior to weeks 4, 8, 12 and EoT.
Change From Baseline to EoT in Mean Volume Voided Per Micturition	Baseline and EoT (up to 12 weeks)	The mean volume voided per micturition was calculated from the data recorded by the participant during 3 consecutive days with volume measurements during the 7-day micturition diary period.
Change From Baseline to EoT in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score	Baseline and EoT (up to 12 weeks)	The OAB-q was a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion consisted of 8 items, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicates an improvement.
Change From Baseline to EoT in Treatment Satisfaction-Visual Analogue Scale (TS-VAS)	Baseline and EoT (up to 12 weeks)	The TS-VAS was a visual analogue scale which asked participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) on the left to 10 (Yes, completely) on the right. A positive change from baseline indicated improvement.
Number of Incontinence Episodes at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The number of incontinence episodes was calculated as the total number of incontinence episodes on valid diary days recorded during the 7-day micturition diary period.
Change From Baseline to Weeks 4, 8, 12 and EoT in Number of Incontinence Episodes	Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)
Change From Baseline to Weeks 4, 8 and 12 in Mean Number of Incontinence Episodes Per 24 Hours	Baseline and weeks 4, 8 and 12
Change From Baseline to Weeks 4, 8 and 12 in Mean Number of Micturitions Per 24 Hours	Baseline and weeks 4, 8 and 12
Change From Baseline to Weeks 4, 8 and 12 in Mean Volume Voided Per Micturition	Baseline and weeks 4, 8 and 12
Change From Baseline to EoT in Corrected Micturition Frequency	Baseline and Week 12	Corrected micturition frequency was defined as the mean number of micturitions per 24 hours that participants had at end of treatment if their fluid intake had remained unchanged since baseline.
Number of Urgency Incontinence Episodes at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	An urgency incontinence episode was defined as the involuntary leakage of urine accompanied by or immediately preceded by urgency. The number of urgency incontinence episodes was the number of times a participant recorded an urgency incontinence episode on valid diary days during the 7-day micturition diary period prior to each visit.
Percentage of Participants With ≥ 10 Points Improvement From Baseline in HRQL Total Score at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The percentage of participants with ≥ 10 points improvement from baseline to each visit (weeks 4, 8, 12 and EoT).
Percentage of Participants for Micturition Frequency Normalization at Weeks 4, 8, 12 and EoT	Weeks 4, 8 , 12 and EoT (up to 12 weeks)	The percentage of participants with micturition frequency normalization was defined as any participant who had ≥ 8 micturitions/24 hours at baseline and \< 8 micturitions/24 h postbaseline at weeks 4, 8, 12 and EoT.
Percentage of Participants With Zero Incontinence Episodes Per 24 Hours Using the Last 7 Diary Days at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The percentage of participants with zero incontinence episodes per 24 hours postbaseline in the last 7 days prior to weeks 4, 8, 12 and EoT.
Percentage of Participants With ≥ 1 Point Improvement From Baseline in PPBC at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The percentage of participants with ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.
Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q Symptom Bother Scale) at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and minimal important difference reached (improvement by ≥ 10 points) on the OAB-q Symptom Bother score at weeks 4, 8, 12 and EoT.
Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 10 Points Improvement on OAB-q HRQL Total Score) at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and minimal important difference reached (improvement by ≥ 10 points) on the OAB-q HRQL total score at weeks 4, 8, 12 and EoT.
Percentage of Participants With Major (≥ 2 Points) Improvement From Baseline in PPBC at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The percentage of participants with a major (≥ 2 points) improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.
Percentage of Participants Who Were Double Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The percentage of participants considered as double responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline and ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.
Percentage of Participants Who Were Triple Responders (50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours, at Least 10 Points Improvement on OAB-q Symptom Bother Scale and at Least 1 Point Improvement on PPBC) at Weeks 4, 8, 12 and EoT	Weeks 4, 8, 12 and EoT (up to 12 weeks)	The percentage of participants considered as triple responders, defined as participants with 50% reduction in mean number of incontinence episodes per 24 hours compared to baseline, minimal important difference reached (improvement by ≥ 10 points) on the OAB-q Symptom Bother score, and ≥ 1 point improvement from baseline in PPBC at weeks 4, 8, 12 and EoT.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)	From first dose of double-blind study drug up to 30 days after last dose of double-blind study drug (up to 16 weeks)	A TEAE refered to an adverse event (AE; defined as any untoward medical occurrence in a participant administered a study drug or who had undergone study procedures and did not necessarily have a causal relationship with this treatment) which started or worsened in the period from first double-blind medication intake until 14 days after the last double-blind medication intake. Serious TEAEs with a start date reported until 30 days after the last double-blind medication intake were also summarized as TEAEs, and also included serious TEAEs upgraded by the sponsor based on review of the sponsor's list of Always Serious terms if any upgrade was done. Drug-related TEAEs may be possible or probable, as assessed by the investigator, or records where relationship is missing.
Change From Baseline to Weeks 4, 8, 12 and EoT in Postvoid Residual (PVR) Volume	Baseline and weeks 4, 8, 12 and EoT (up to 12 weeks)	PVR volume was assessed by ultrasonography or a bladder scanner.
Change From Baseline to Weeks 4, 12 and EoT in Mean 24-hours, Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP)	Baseline and weeks 4, 12 and EoT (up to 12 weeks)	Vital signs (blood pressure and pulse rate) were monitored using an ambulatory blood pressure monitoring (ABPM) device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.
Change From Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP)	Baseline and weeks 4, 12 and EoT (up to 12 weeks)	Vital signs (blood pressure and pulse rate) were monitored using ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.
Change From Baseline to Weeks 4, 12 and EoT in Mean 24-h, Mean Daytime and Mean Nighttime Pulse Rate (PR)	Baseline and weeks 4, 12 and EoT (up to 12 weeks)	Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours.
Change From Baseline to Weeks 4, 12 and EoT in Mean PR in the Tmax Window	Baseline and weeks 4, 12 and EoT (up to 12 weeks)	Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose.
Change From Baseline to Weeks 4, 12 and EoT in Mean SBP in the Time to Maximum Concentration (Tmax) Window	Baseline and weeks 4, 12 and EoT (up to 12 weeks)	Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax (time to maximum concentration) window of mirabegron and solifenacin was from 4-6 hours postdose.
Change From Baseline to Weeks 4, 12 and EoT in Mean DBP in the Tmax Window	Baseline and weeks 4, 12 and EoT (up to 12 weeks)	Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose.
Maximum 1-hour Change From Time-matched Baseline in DBP at Weeks 4, 12 and EoT	Baseline and weeks 4, 12 and EoT (up to 12 weeks)	Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose. The maximum 1 hour change from time-matched baseline was calculated as the maximum difference between the post-baseline hourly means and the time-matched baseline hourly means.
Maximum 1-hour Change From Time-matched Baseline in SBP at Weeks 4, 12 and EoT	Baseline and weeks 4, 12 and EoT (up to 12 weeks)	Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. The maximum 1 hour change from time-matched baseline was calculated as the maximum difference between the post-baseline hourly means and the time-matched baseline hourly means.
Maximum 1-hour Change From Time-matched Baseline in PR at Weeks 4, 12 and EoT	Baseline and weeks 4, 12 and EoT (up to 12 weeks)	Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Tmax window of mirabegron and solifenacin was from 4-6 hours postdose. The maximum 1 hour change from time-matched baseline was calculated as the maximum difference between the post-baseline hourly means and the time-matched baseline hourly means.
Change From Baseline to Weeks 4, 12 and EoT in SBP Peak/Trough Difference	Baseline and weeks 4, 12 and EoT (up to 12 weeks)	Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference was defined as the difference between the highest 1-h to lowest 1-h average per participant per visit.
Change From Baseline to Weeks 4, 12 and EoT in DBP Peak/Trough Difference	Baseline and weeks 4, 12 and EoT (up to 12 weeks)	Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference was defined as the difference between the highest 1-h to lowest 1-h average per participant per visit.
Change From Baseline to Weeks 4, 12 and EoT in PR Peak/Trough Difference	Baseline and weeks 4, 12 and EoT (up to 12 weeks)	Vital signs (blood pressure and pulse rate) were monitored using an ABPM device placed on the upper arm followed by intake of the double-blind study medication and worn for at least 24 hours. Peak/trough difference was defined as the difference between the highest 1-h to lowest 1-h average per participant per visit.

Trial Locations

Locations (435): Site US10049 Coastal Clinical Research, Inc.
🇺🇸
Mobile, Alabama, United States
Site US10112 TFI, LLC
🇺🇸
Mobile, Alabama, United States
Site US10104 Clinical Research Advantage, Inc.
🇺🇸
Chandler, Arizona, United States
Site US10021 Beach Clinical Studies
🇺🇸
Phoenix, Arizona, United States
Site US10122 Orange County Research Institute
🇺🇸
Anaheim, California, United States
Site US10098 Skyline Research
🇺🇸
Cerritos, California, United States
Site US10539 Citrus Valley Medical Research
🇺🇸
Glendora, California, United States
Site US10082 American Clinical Trials
🇺🇸
Hawaiian Gardens, California, United States
Site US10132 Axis Clinical Trials
🇺🇸
Los Angeles, California, United States
Site US10133 Axis Clinical Trials
🇺🇸
Los Angeles, California, United States
Scroll for more (425 remaining)
Site US10049 Coastal Clinical Research, Inc.
🇺🇸Mobile, Alabama, United States